Cancer Chemotherapy and Pharmacology

, Volume 32, Issue 6, pp 496–497

Acute mucocutaneous toxicity following high-dose hydroxyurea

  • Hans Brincker
  • Bjarne Egelund Christensen
Short Communication High-Dose Hydroxyurea, Mucocutaneous Toxicity

Abstract

Three patients with advanced acute myeloid leukemia were treated with oral high-dose hydroxyurea at a dose of 10 g daily for 8–10 days. Severe acute stomatitis developed in all three patients. In addition, two of the patients developed a peculiar acute cutaneous type of toxicity associated with soreness, violet erythema, and edema of the palms and foot soles followed by intense universal hyperpigmentation of the skin. Apparently, the pronounced acute mucocutaneous toxicity was caused by the sustained high daily dose of hydroxyurea, indicating that myelosuppression may not be the dose-limiting toxicity of this drug.

References

  1. 1.
    Donehower RC (1992) An overview of the clinical experience with hydroxyurea. Semin Oncol 19 [Suppl 8]: 11Google Scholar
  2. 2.
    Grund FM, Armitage JO, Burns CP (1977) Hydroxyurea in the prevention of the effects of leucostasis on acute leukemia. Arch Intern Med 137: 1246Google Scholar
  3. 3.
    Kennedy BJ (1992) The evolution of hydroxyurea therapy in chronic myelogenous leukemia. Semin Oncol 19 [Suppl 8]: 21Google Scholar
  4. 4.
    Kennedy BJ, Smith LR, Goltz RW (1975) Skin changes secondary to hydroxyurea. Arch Dermatol 111: 183Google Scholar
  5. 5.
    Kolitz JE, Kempin SJ, Schluger A, Wong GY, Berman E, Jhanwar S, Arlin ZA, Gee T, Clarkson BD (1992) A phase II pilot trial of high-dose hydroxyurea in chronic myciogenous leukemia. Semin Oncol 19 [Suppl 8]: 27Google Scholar
  6. 6.
    Landgren RC, Hussey DH, Barkley HT, Samucls ML (1974) Splitcourse irradiation compared to split-course irradiation plus hydroxryurea in operable bronchogenic carcinoma. Cancer 34: 1598Google Scholar
  7. 7.
    Lokich JJ, Moore C (1984) Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101: 798Google Scholar
  8. 8.
    Vaughan WP, Bierman PJ, Reed EC, Glenn LD, Kessinger A, Armitage JO (1992) High dose hydroxyurea in autologous bone marrow transplantation: a promising “new” agent. Semin Oncol 19 [Suppl 8]: 110Google Scholar
  9. 9.
    Veale D, Cantwell BMJ, Kerr N, Upfold A, Harris AL (1988) Phase I study of high-dose hydroxyurea in lung cancer. Cancer Chemother Pharmacol 21: 53Google Scholar
  10. 10.
    Yarbro JW (1992) Mechanism of action of hydroxyurea. Semin Oncol 19 [Suppl 8]: 1Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Hans Brincker
    • 1
  • Bjarne Egelund Christensen
    • 1
  1. 1.Department of HematologyOdense University HospitalOdense CDenmark

Personalised recommendations